� � � ����������Vol. 37, pp. 125�132, 2009
����������� ����������������������� !"�����
������
������
� � :�� 21� 2 � 16��
����
�� �������������� ����������������������� �!�"�#$��%&� !'��()*�+,��-�./01��# 2& �����������3�45678*�+�2�)������9�4�:�78*�+��#;<=��>�?@�A�B C�8 DEF!�G"�?HI;�?@J#K��LMNO�KP@ �Q�RS$%&T)K I;J#UK';J#� 15�VW4(X );�6YQ�*@Z��[+-�8;J�\�@�])P@�-�,6H^* _�`ab���KI;�-� 2cd�?e��!4#$�^�+feQ1� gh�)�I;=.�-/�i/�jkj�l*8� 2� �AI;�-#@��F! 3� G�I;�-#@��F! 4� I;�-#@m012=.�_�`ab�n3��oghZp4�8*@��qj�j�%l)P@��l*8r$@�-�#@
1. ��� ���������������
i/�jkj-K �;�5hst6�u7�849v#@w:-�8 ;x�o=.�F!�y<#@Z�� -=z��8��o 2cK{i/>�*6|@{;}: cytotoxic drugs +,)^/?~:2F!Z����0 �w:s@�AB�w:���KCcCD�w:-�8�) E�*9��^HllP@�-4 K�X��F�8���*��^o�gh�-�fI;��,@ �2^
i/�jkjK5h�^* gh CEA carcino-embryonic antigen�1, 2� CA19-93� AFP a-fetopro-tein�4� CA72-45� NCC-ST-4396�^do�:��8�H ;x��)5<��8*@ CEAK 1965��k��� Gold- Freedman�?HB��� �1Q��Z�/G<��8���jkj<��%l)P@ �Q� I;'H�I�JK CA19-9 4KL-#@������ A��j��M�{� CA19-9 CA50 SPan-1� s���� Tn{���j�CA72-4 STn CA546� �No�/ Cc-�O�Z�*-��:ZP@ �� CA72-4 - NCC-ST-439KG�I;)�I�Jo�/F!��jkj-^HP@ ���Q@��CD�K �o�/^@ CEA - CA19-9 -�R��67oS�-���� n@�)K CEA, CA19-9 AFP �R��67o TUVu)K CA125 oS<-��8*@ �Q� gh�-�fi/�jkj�d�ZoWX�*/ ¡��Y�8*@-K**Z/ �A=.�KW[`a¢\£<� �¤¥=.o¦�)PH ��f§�]A=. @��S^s§c¨��©ª«j�¬��5<��@�-o_*m� `��?@ a4GnT ®a~4¯j°¬±-��I;�?~=.o �A=.�S<)P@²A�Q�bc��8*@7� I;d³t6) �2��g�8*@G1cNAca1 4Ga1ß��K I;t6)Z�e��g�8*@�-4l�-X ��M�KI;�fM�{��%l-=z��8*@ ��� G1cNAca1 4Ga1ß ��4��#@M@�´g a4GnT KI;t6)Z�e��g4=X µhP@¶� a4GnTmRNA K I;t6odUP@*KdU·R¸�¹º#@�A;)Z C�»� 80.0�� 56.3���¼i)<��� I���������� ��� `ab�n3���
125
49
��������������������� �� ��������������� �������������������������� ���������������� !"�#$ �pepsinogen; PG� �%&'�($)�*+�,*-�./'%&����*+���01��+��� *�*��� 23�45'67��8�� 59$:$ �;<��=��>�?@� ��� !"�#$��AB7�� C�D�EFG01��!H*,"���I���#$%���,�1��
2. ����������
�����&J�� ��'(�)* �m� KL�)*M+ �sm� ��NK�,����� O���,�'(�'$P-.QRS��-� /3�01T�O��?�� U�234K����������,5VW�?�6789�X5VW�)*67::EMR �endoscopic mucosal resection�����;1<�Y5Z�[S�89=\��]L�2004 3� ��^_�?@`>��L��89a
/bc/$�?�d EMR�?e�� @A�B,GCf�������� 2 cm g5�)*�����hD�O�� 19623?@ 19993K��iEjk$l�Fm@n�of�LG����� 3261;1�pHIq�,f��?r�� EMR ?e;1�fH� 8���Ts��� t3� 5VWuv�5VWwx��y�JK�?@LL�5VW�67:���X5VW�)*M+MN: �ESD: endoscopic sub-mucosal dissection�zE��� iEjk$l�Fm@n� O{|jk$l�G�}~P-��Q�89����]+��8, 9�� ,��jR�'�$�uZS^<�Y��T5Z�[�+,89����@� ���<�Y��T5ZU�� 4VW�uvGFX�*L ESD ���YK�+��10�� ESD�� �U+� EMR��C�@� 5VW����G�*+Z[���\��%G�5�D]^*_@�)*M+GMs`�89����� O��?@� a%� EMR ����67���b 2 cm ��]L��c*� 10 cm gd�,����@� S��[?�B,��e�?��:�f�p7��L� ��)*5��NK��������dS���f��-67?e�������r�� iEjk$l�[?�j��g@n�?��95%�&����
pHIq�?�d������h � )*��[�+� 3 cm g5���d@AiB,��e��f�H'$P-.Q� 0�� �95��CI: 0�0.3��� ��@�B,GCf��h ��S���f��-'$P-.Q� 0�� �95��CI: 0�0.4�����]L� ���)*M+�(*L������h � sm1jk �500mm�K�¡U� 3 cmg5���d 0�� �95��CI: 0�2.5������11�� O���T¢+G ESD �?e;1�*Lh � a%� EMR ��G������ 8���£s��]L� 28���K���O�lm*+[@� �����89�S�-¤¥T�O��m������ ���gn'$P-.Q��e� TY.Q��eG:4������LL�������¦U�]Lh � ���?e=\§����Go~+����1��
3. �������������
<�Y5Z�[S�po��D�89�� 67q��¨���cr��@s�� t3���bt2��>©ª����,��h@�po����@� «u�*+po��;1�cT�v:9�,*-�� ¬j<�?��^9�G�}~�*Lw^�89�����O��Af@������� 67q�po�¨����cT��^9��� x��89��$Ay��+��� zR����{|89}<[?�~��zE��+[�H� i5®����¯>�G°�*L���±�Fm� �median survival time: MST� �[[? 6�9²³��@� ���$%�>������ *�*��� O����^9��I*� "����53gd�Gs��+���2;1��T�O�,KL������ O���� ��89������ �^9��67q�po�¨�;1�c*+�����0����¢�v������1�����´N�?r�*+}<G��T¢����r�� 2004 3�µ&���^_�o*L��89a/bc/$�?�d� ���cT�{|��^9��*+� ¶·�4'¸$ �5-FU ���!% c�$ �CDDP� G¹º�^9�������i5®����¯>���,����� &���$G��T�O������� ��]+���i5����¯�[�+t3��V���,���U� JCOG �Japan Clinical Oncology Group� ��� JCOG9912 ���¯�@� »3�i ASCO
��¼o126
50
2007 �Chicago, US� ����������� A : 5FU ������� B : CPT-11�CDDP� C : S-1� 3 ������������� �!"#$� A : 2.9%&� B : 4.8%& �Hazard Ratio;0.69, p�0.001�� C : 4.2%& �Hazard Ratio; 0.75,p�0.0001� '��� B()* C �+,$ 5FU ��+,�-.�/0������� �12.�3�� 4�� 5��� �!"#$� A : 10.8%&�B : 12.3%& �Hazard Ratio; 0.85, p�0.05�� C :11.4%& �Hazard Ratio; 0.83, p�0.001�'��� B �678$9:��� �� C �;<=$
>?�� @A$ S-1+,�BC+,'.�DE�FGH�I��3F� .�.���� J�KLMNO$ S-1 ��)�P S-1�CDDP �QR,S�T�UVOWF'�XYPW�� Z5�FBC+,S�[\�$]^�3�312�� _`� abcdefghijO$� klm�nophqr� stuvgwx!y'.�lj,Sz{|�}~��3F�@A$��BC+,��:O��3�����OWF ������ ����� ����� ��� Q����/��������O$+,S��{�{���l��_O��3�3� �'x�4�� ���
� 1
� 1
�� ¡�+,�(¢F_£'¤�� ¡TS�¥� 127
51
���������������� �������������������������������� � !��� 5FU �"#$%&'(#��)*+ CYP2A6� TSER� MTHFR� DPD �,-./� �SNP� +�0�113�� CDDP �(23'45��)*+ GSTP114�� CPT-11 �6789�5��)*+ UGT1A1� ABCB1� ABCC215�� SNP +�0�1:;<���=� ��:>�?�@�� �A���, ��=BCD EGFR E8F%GH#BI� �cetuximab� panitumumab� :��<�� ��A�)*� KRAS J���K���:L+�=M+:��N��=16�� ��� �OP��Q��A��RS=T��������U� +V�J���0!=,���UWX#��Q��=M+?�YZ[����=� <��� �O\�<�=M+�]�^_`_�a��bc�de�f!M+:g�+����� �
4. ����������
hi��!=j !��k"��l<�=��?� �mV 2 +nS�=� , ?� 2F7H�5
o+N��`_�k"#$� � , ?� pqr���Q_A�$�st=_t�k"#$��=�2F7H�5ouv+N�� wx�y%zH�H� &{|uv}~����uv���?��=k"'(��)!=�?�*��=� ��hi���k"�?&{|uv�]=�uuv:g����� �+q�+Q���N�,���+?��:_� �B��-�� B����&.pq�f�� �u��S��k"!=,����k"#$���&{|� ������$� �/���� �NBI: NarrowBand Imaging�:�=:sN�01k"�T���2=�?�Q�����hi$H H�6¡A�s��_t�k"#$?�¢]�lt���m_:£¤+N�¥���Q����� M�?01¦§� 0�3¨� 0�4©� 0�� 5xªp����f�«�¬���?¥��m����M+�®N��=� ¯°?<��,����±6���� 7:>� �²³´1� 8µ'�f����������������¶�·¸�u9!=M+:g���=�¹�?� M� 2 ��l�:º=»V� J���
2
;<¼�128
52
���������� ������� ���� �� �������������������������� ���������� �� !��"#17�� ����������$����%��&�'#($�� )�*+�,$��-�.#���/0�"1� � ���234565 7DNA��89:����;���&�<�.#=�#8>?@A$���BCD�E#� � F� -�������������G��������H1I��J� ����;���G���������� H1�<�CD�� -���E#($G.� ����K1� LM�� Helicobacter Pylori NO$�-� !�PCD�E#18�21�� (DQ�R�GS�;���G89:���E#T HU�� �VNWX� YZ[\�]�� ^_�]�� �`G�a��#b�XGM��cCDdd"1� efgh5>5$���ij�kE�l��F� K�#�������������&��� mn� op.q���& MD rZ
s5tZGSuZ65� Jean-Pierre J Issa v��w�xyz{��{|}� !~������:52$$ ������22�, 23�� (����� 89:����ZNWX;��, H#�"&��($ H1��� 89:� DNA �#&�Z2:gDNA TQ��.#($G��� hf3r�f�� H1� DNA 89:������&op.#$E� ��"# �methylated genes genome-wideby hybridizing a CpG island microarray with am-
plicons obtained by the methylated CpG island
amplification technique: MCAM�� (�mn���.� ��������� ���Z2:�������� KE� �$�mn��&%#�� Z¡��¢Z£¤G¥&��K1� '¦§(¨)©`����89:�&mn.#($ H1� �{)� ª.#*«X� �]�m�Gb��"1� ��F�¨)�g5s58f¬� z�����#�� 1������������&®+$�����¯°�±²³´$��� µ¶�,- �·� .� /
� 2
F�¸��¨) K�#¹º$»�¸����¼� 129
53
�� ���������������� ����24�, 25�� ����������� DNA ����������������������� � � ��� pH1-3 ���� !��"�#��� DNA ��#�$%�&'� � �����(�)�*���+DNA�,-�� ����� � � �./01�����������2345��67845�9:;�<�=>� ��?�@A#��� BA�CDE�����)#������F)CD��G���H� I�����!"���)���CD�JKA�� ����#LM$���./%&�N)#OP�F� 'Q@A�� R�� 9:;�<(S#)*��+�J�� ����./01E� OP'Q@A�B������,-)� DNA �./)TU6VWXYZ[�\ �]0�)�01�)�� )*�123�����4�^5_�� ��J`�����67���*��a89M:� ��!b���;<�cde0"f=� g>�+?hi@A�B����@ABC�0"M:�j DRA#����>�����Rk� lE�����mFnGo=>
MCAM � ��A� 146mFnGo�� 8��*�p���#HI9DNA78qr,JI��st:u�[T53� 38mFnGo�K/)� �� 1�� BA��nGoL)� v5wxKM)���NOPQR DNA �n�6� �� yv5XYzNO�S ���DNA �n�6����#78qr,J�J�� 78qr{|q�0Tr)��+� ROC �Reciver Operating Characteristic� ��}���#U~�� �4� V\4� PPV, NPV ��H� jW9 5mFnGo�K/)� �� 2���BA� 5mFnGo���#� �� 153XY
�59q���PQRZ0��� DNA: T�20�� ���[@PQRZ0��� DNA: N�20�� ��������� DNA: W�20�� yv5XYz�S ����� DNA: EN�48�� yv5XYzS ��������DNA: EW�48����0\�J��� ]��!#�78qr{|q�0Tr)��+�ROC �Reciver Operating Characteristic� ��}���#U~�� �4� V\4� PPV, NPV ��H^��J�� �� 2� � 3����� ������M:)�DNAI�� ���Z0 2�� ./)�DNA� ���_�� R�[��XY� �GI���� @�� �MmF�)� 5nGo�78qr\ ��`4��aH� ��I MINT25 �j UA�����mFI� �4 �90���� V\4 �96���� AUC �0.961���)�� �bc�B�� Z0de������./)� gDNA ��78qr,J������#� 5mFnGo��#!�f�)#� ���������gaI��B��h��#���� ��./01E'Q)#���������� TU6VWXYZ[�\ ������B��@ g�I��B��\i@A� ���XY����-]���� _�j��XY�k����R�#��� �I���� �]� >I��¡l¢£m¤�� B�ni�o�p¥�r¦¤§¨2©qI� � ]EVªrs)#��26���tRI�� �J��� «]u��e�
�� ¬vwZx� yz®{1x� |}~�1x¯)#�r¦�°��£�3±Z²� ¥��d³5±��./R� ¡l¢£m¤�d� ���´�µ�£¤¶·� Zr¤¶·���¸x� X¹�3m¤ MD z5w�º5�d³5±��»�£�Jean-Pierre J Issa �Z� Hyun Soo Kim �Z�
� 3
��¼J130
54
Ryan J Castoro ���������
� �
1� Gold JM, Freedman SO, Gold P. Human anti-CEA antibodies detected by radioimmunoelec-
trophoresis. Nat New Biol 1972; 239: 60�62.2� Gold P, Shuster J, Freedman SO. Carcinoem-bryonic antigen �CEA� in clinical medicine: his-torical perspectives, pitfalls and projections.
Cancer 1978; 42: 1399�1405.3� Arakawa Y, Ariga H, Kano M, Matsuo Y,Honda T, Morita K. Determination and sig-
nificance of a new carbohydrate antigen CA19-
9 in digestive system cancers. Jpn J Med 1985;
24: 121�130.4� Masuzawa M, Lee PK, Kamada T, AkeyamaT, Abe H, Shimano T, Mori T, Morino H,
Ishiguro S. Carcinoembryonic antigen, alpha-
fetoprotein and carcinoplacental alkaline phos-
phatase in gastric carcinoma metastatic to the
liver. Cancer 1977; 39: 1175�1180.5� Byrne DJ, Browning MC, Cuschieri A. CA72-4: a new tumour marker for gastric cancer. Br
J Surg 1990; 77: 1010�1013.6� Ohkura H, Hattori N, Miyazaki I, Sawabu N,Tobe R, Kawai K, Abe O, Ishii M, Kawai T,
Kamano T,. �Clinical study of the NCC-ST-439 EIA kit using serum from patients with
various types of cancer and benign disease �1��.Gan To Kagaku Ryoho 1987; 14: 1901�1906.
7� Nakayama J, Yeh JC, Misra AK, Ito S, Kat-suyama T, Fukuda M. Expression cloning of a
human alpha1� 4-N-acetylglucosaminyltrans-ferase that forms GlcNAcalpha1� 4Galbeta� R, a glycan specifically expressed in the gas-tric gland mucous cell-type mucin. Proc Natl
Acad Sci U S A 1999; 96: 8991�8996.8� Kondo H, Gotoda T, Ono H, Oda I, Kozu T,Fujishiro M, Saito D, Yoshida S. Percutaneous
traction-assisted EMR by using an insulation-
tipped electrosurgical knife for early stage gas-
tric cancer. Gastrointest Endosc 2004; 59: 284�288.
9� Ono H, Kondo H, Gotoda T, Shirao K, Ya-
maguchi H, Saito D, Hosokawa K, Shimoda
T, Yoshida S. Endoscopic mucosal resection
for treatment of early gastric cancer. Gut 2001;
48: 225�229.10� Watanabe Y, Kato N, Maehata T, OkamotoM, Tsuda T, Hattori S, Yamauchi S, Fujita K,
Baba S, Nakaya S, Inaba H, Kitajima S,
Suzuki M, Niwa H, Itoh F. Safer endoscopic
gastric mucosal resection: preoperative proton
pump inhibitor administration. J Gastroen-
terol Hepatol 2006; 21: 1675�1680.11� Gotoda T, Yanagisawa A, Sasako M, Ono H,
Nakanishi Y, Shimoda T, Kato Y. Incidence
of lymph node metastasis from early gastric
cancer: estimation with a large number of cases
at two large centers. Gastric Cancer 2000; 3:
219�225.12� Wasaburo K, Tanabe S, Higuchi K, Sasaki T,
Nakayama N, Mihara S, Nakatani K,
Nishimura K, Shimoda T, Azuma M, Katada
C, Hanaoka N, Naruke A, Ryu T, Ishido K,
Saigenji K. �Clinical development of S-1 �TS-1�for advanced gastric cancer�. Gan To KagakuRyoho 2006; 33 Suppl 1: 57�63.
13� Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H,Carr KL, Houghton M, Urrea P. Phase I phar-
macokinetic study of S-1 plus cisplatin in pa-
tients with advanced gastric carcinoma. J Clin
Oncol 2005; 23: 6957�6965.14� Pasello M, Michelacci F, Scionti I, HattingerCM, Zuntini M, Caccuri AM, Scotlandi K,
Picci P, Serra M. Overcoming glutathione S-
transferase P1-related cisplatin resistance in os-
teosarcoma. Cancer Res 2008; 68: 6661�6668.15� Corona G, Vaccher E, Sandron S, Sartor I,Tirelli U, Innocenti F, To#oli G. Lopinavir-
ritonavir dramatically a#ects the pharmacoki-
netics of irinotecan in HIV patients with Ka-
posi[s sarcoma. Clin Pharmacol Ther 2008; 83:
601�606.16� Di NF, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De DS, Mazzuc-
chelli L, Frattini M, Siena S, Bardelli A. Wild-
type BRAF is required for response to panitu-
�� �������������� ������ 131
55
mumab or cetuximab in metastatic colorectal
cancer. J Clin Oncol 2008; 26: 5705�5712.17� Watanabe Y, Toyota M, Kondo Y, Suzuki H,Imai T, Ohe-Toyota M, Maruyama R, Nojima
M, Sasaki Y, Sekido Y, Hiratsuka H, Shino-
mura Y, Imai K, Itoh F, Tokino T. PRDM5
identified as a target of epigenetic silencing in
colorectal and gastric cancer. Clin Cancer Res
2007; 13: 4786�4794.18� Ushijima T, Sasako M. Focus on gastric can-cer. Cancer Cell 2004; 5: 121�125.
19� Horii A, Nakatsuru S, Miyoshi Y, Ichii S,Nagase H, Kato Y, Yanagisawa A, Nakamura
Y. The APC gene, responsible for familial
adenomatous polyposis, is mutated in human
gastric cancer. Cancer Res 1992; 52: 3231�3233.20� Nanus DM, Kelsen DP, Mentle IR, Altorki N,Albino AP. Infrequent point mutations of ras
oncogenes in gastric cancers. Gastroenterology
1990; 98: 955�960.21� Maesawa C, Tamura G, Suzuki Y, OgasawaraS, Sakata K, Kashiwaba M, Satodate R. The
sequential accumulation of genetic alterations
characteristic of the colorectal adenoma-
carcinoma sequence does not occur between
gastric adenoma and adenocarcinoma. J Pa-
thol 1995; 176: 249�258.22� Estecio MR, Yan PS, Ibrahim AE, Tellez CS,Shen L, Huang TH, Issa JP. High-throughput
methylation profiling by MCA coupled to CpG
island microarray. Genome Res 2007; 17:
1529�1536.23� Estecio MR, Gharibyan V, Shen L, IbrahimAE, Doshi K, He R, Jelinek J, Yang AS, Yan
PS, Huang TH, Tajara EH, Issa JP. LINE-1
hypomethylation in cancer is highly variable
and inversely correlated with microsatellite in-
stability. PLoS ONE 2007; 2: e399.
24� Belinsky SA, Klinge DM, Dekker JD, SmithMW, Bocklage TJ, Gilliland FD, Crowell RE,
Karp DD, Stidley CA, Picchi MA. Gene pro-
moter methylation in plasma and sputum in-
creases with lung cancer risk. Clin Cancer Res
2005; 11: 6505�6511.25� Itzkowitz SH, Jandorf L, Brand R, RabeneckL, Schroy PC, III, Sontag S, Johnson D,
Skoletsky J, Durkee K, Markowitz S, Shuber
A. Improved fecal DNA test for colorectal
cancer screening. Clin Gastroenterol Hepatol
2007; 5: 111�117.26� Watanabe Y, Kim HS, Castoro R, Chung W,Estecio M, Kondo K, Guo Y, Ahmed S, Toy-
ota M, Itoh F, Suk K, Cho M, Shen L, Jelinek
J, Issa J. Sensitive and Specific Detection of
Early Gastric Cancer Using DNA Methylation
Analysis of Gastric Washes. Gastroenterology
2009; inpress.
����132
56